Physician profile
Christina Andre
NPI 1598034936
$2,067.01
in general payments reported to CMS, 2019-2025
28 companies · $694 in 2025
The $694 reported for 2025 was more than what 80% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $115 · 2022: $402 · 2023: $244 · 2024: $612 · 2025: $694.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,550.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,549.97 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $530.27 | 2021-2025 | |
| Astrazeneca Pharmaceuticals LP | $132.23 | 2023-2025 | |
| Astellas Pharma US INC | $120.45 | 2024-2025 | Veozah |
| Biogen, INC. | $117.65 | 2024 | Zurzuvae |
| Lilly USA, LLC | $110.67 | 2022-2024 | Mounjaro |
| Pfizer INC. | $109.82 | 2022-2025 | |
| Exact Sciences Corporation | $99.58 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Mylan Specialty L.P. | $97.50 | 2024 | Yupelri |
| Novo Nordisk INC | $93.52 | 2022-2025 | Rybelsus, Ozempic, Wegovy |
| Bayer Healthcare Pharmaceuticals INC. | $89.22 | 2021-2025 | |
| Inspire Medical Systems, INC. | $66.67 | 2025 | Inspire |
| Boehringer Ingelheim Pharmaceuticals, INC. | $61.37 | 2021-2022 | |
| Supernus Pharmaceuticals, INC. | $57.38 | 2024-2025 | Qelbree |
| Otsuka America Pharmaceutical, INC. | $53.75 | 2025 | Rexulti |
| Sunovion Pharmaceuticals INC. | $44.78 | 2021 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $37.53 | 2024 | Caplyta |
| Merck Sharp & Dohme LLC | $27.93 | 2023 | Belsomra, Steglatro |
| Glaxosmithkline, LLC. | $27.79 | 2023-2025 | Arexvy, Shingrix, Bexsero |
| Biohaven Pharmaceutical Holding Company LTD. | $24.10 | 2022 | |
| Viatris Specialty LLC | $23.47 | 2025 | Yupelri |
| Coopersurgical, INC. | $22.84 | 2025 | Paragard T 380a |
| Ultragenyx Pharmaceutical INC. | $22.00 | 2023 | |
| E.R. Squibb & Sons, L.L.C. | $18.04 | 2022 | |
| Daiichi Sankyo INC. | $17.45 | 2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $17.27 | 2025 | Xifaxan |
| Neurocrine Biosciences, INC. | $15.18 | 2023 | Ingrezza |
| Amgen INC. | $14.35 | 2024 | Otezla, Repatha |
| Cranial Technologies, INC | $14.20 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Christina Andre listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.